메뉴 건너뛰기




Volumn 29, Issue 5, 2011, Pages 858-864

Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy

Author keywords

Ankylosing spondylitis; Efficacy; Etanercept; Psoriatic arthritis; Spondiloarthropathies

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 83455173656     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (17)

References (70)
  • 1
    • 71249140249 scopus 로고    scopus 로고
    • Biologies in the treatment of rheumatoid arthritis and ankylosing spondylitis
    • BRAUN J, KALDEN JR: Biologies in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl.55):S 164-7.
    • (2009) Clin Exp Rheumatol , vol.27 , Issue.SUPPL.55 , pp. 164-167
    • Braun, J.1    Kalden, J.R.2
  • 2
    • 79955844276 scopus 로고    scopus 로고
    • For the assessment of SpondyloArthritis international society 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
    • VAN DER HEIJDE D, SIEPER J, MAKSYMOWYCH WP et al:. for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-8.
    • (2011) Ann Rheum Dis , vol.70 , pp. 905-908
    • Van Der Heijde, D.1    Sieper, J.2    Maksymowych, W.P.3
  • 3
    • 79955826864 scopus 로고    scopus 로고
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    • BRAUN J, VAN DEN BERG R, BARALIAKOS X et al:. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
    • (2011) Ann Rheum Dis , vol.70 , pp. 896-904
    • Braun, J.1    Van Den Berg, R.2    Baraliakos, X.3
  • 4
    • 38549176118 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
    • TRACEY D, KLARESKOG L, SASSO EH, SALFELD JG, TAK PP: Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008; 117: 244-79.
    • (2008) Pharmacol Ther , vol.117 , pp. 244-279
    • Tracey, D.1    Klareskog, L.2    Sasso, E.H.3    Salfeld, J.G.4    Tak, P.P.5
  • 5
    • 37849052961 scopus 로고    scopus 로고
    • TNFa blockade in human diseases: Mechanisms and future directions
    • WONG M, ZIRING D, KORIN Y et al.: TNFa blockade in human diseases: Mechanisms and future directions. Clin Immunol 2008; 126: 121-36.
    • (2008) Clin Immunol , vol.126 , pp. 121-136
    • Wong, M.1    Ziring, D.2    Korin, Y.3
  • 6
    • 0035894504 scopus 로고    scopus 로고
    • Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore
    • DOI 10.1006/abio.2001.5380
    • SANTORA LC, KAYMAKCALAN Z, SAKORAFAS P, KRULL IS, GRANT K: Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299: 119-29. (Pubitemid 34053400)
    • (2001) Analytical Biochemistry , vol.299 , Issue.2 , pp. 119-129
    • Santora, L.C.1    Kaymakcalan, Z.2    Sakorafas, P.3    Krull, I.S.4    Grant, K.5
  • 8
    • 36349029627 scopus 로고    scopus 로고
    • Etanercept: A review of its use in the management of ankylosing spondylitis and psoriatic arthritis
    • HOY SM, SCOTT U: Etanercept. A review of its use in the management of ankylosing spondylitis and psoriatic arthritis. Drugs 2007; 67: 2609-33. (Pubitemid 350159169)
    • (2007) Drugs , vol.67 , Issue.17 , pp. 2609-2633
    • Hoy, S.M.1    Scott, L.J.2
  • 9
    • 0034888069 scopus 로고    scopus 로고
    • Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
    • DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
    • ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86. (Pubitemid 32758236)
    • (2001) Arthritis and Rheumatism , vol.44 , Issue.8 , pp. 1876-1886
    • Anderson, J.J.1    Baron, G.2    Van Der Heijde, D.3    Felson, D.T.4    Dougados, M.5
  • 10
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondilytis disease activity index
    • GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondilytis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
    • (1994) J Rheumatol , vol.21 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3    Whitelock, H.4    Gaisford, P.5    Calin, A.6
  • 12
    • 0028579768 scopus 로고
    • A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index
    • CALIN A, GARRETT S, WHITELOCK H et al:. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5 .
    • (1994) J Rheumatol , vol.21 , pp. 2281-2285
    • Calin, A.1    Garrett, S.2    Whitelock, H.3
  • 13
    • 0037007683 scopus 로고    scopus 로고
    • Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a
    • DOI 10.1056/NEJMoa012664
    • GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. A' Engl J Med 2002; 346: 1349-56. (Pubitemid 34754607)
    • (2002) New England Journal of Medicine , vol.346 , Issue.18 , pp. 1349-1356
    • Gorman, J.D.1    Sack, K.E.2    Davis Jr., J.C.3
  • 14
    • 1842628884 scopus 로고    scopus 로고
    • Results from an open-label extension study of etanercept in ankylosing spondylitis [3]
    • DAVIS JC, WEBB A, LUND S, SACK K: Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 2004; 52: 302-4. (Pubitemid 38468720)
    • (2004) Arthritis Care and Research , vol.51 , Issue.2 , pp. 302-304
    • Davis Jr., J.1    Webb, A.2    Lund, S.3    Sack, K.4
  • 20
    • 67149115523 scopus 로고    scopus 로고
    • Etanercept in the longterm treatment of patients with ankylosing spondylitis
    • DIJKMANS BAC, EMERY P, HAKALA M et al:. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36: 1256-64.
    • (2009) J Rheumatol , vol.36 , pp. 1256-1264
    • Dijkmans, B.A.C.1    Emery, P.2    Hakala, M.3
  • 21
    • 73449140249 scopus 로고    scopus 로고
    • Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis
    • BRAUN J, HUANG F, BURGOS-VARGAS R et al:. Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: S415.
    • (2008) Arthritis Rheum , vol.58
    • Braun, J.1    Huang, F.2    Burgos-Vargas, R.3
  • 22
    • 76649091242 scopus 로고    scopus 로고
    • Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA
    • PAVELKA K, FOREJTOVA S, STOLFA J et al:. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA, Clin Exp Rheumatol 2009; 27: 958-63.
    • (2009) Clin Exp Rheumatol , vol.27 , pp. 958-963
    • Pavelka, K.1    Forejtova, S.2    Stolfa, J.3
  • 23
    • 1042290332 scopus 로고    scopus 로고
    • Once-Weekly Administration of 50 mg Etanercept in Patients with Active Rheumatoid Arthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    • DOI 10.1002/art.20019
    • KEYSTONE EC, SCHIFF MH, KREMER JM et al:. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results ofamulticenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63. (Pubitemid 38198818)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.2 , pp. 353-363
    • Keystone, E.C.1    Schiff, M.H.2    Kremer, J.M.3    Kafka, S.4    Lovy, M.5    De Vries, T.6    Burge, D.J.7
  • 25
    • 34447302822 scopus 로고    scopus 로고
    • Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
    • DOI 10.1093/rheumatology/kem069
    • BRAUN J, MCHUGH N, SINGH A, WAJDULA JS, SATO R: Improvement in patient-reported outcomes from patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007; 46: 999-1004. (Pubitemid 47062511)
    • (2007) Rheumatology , vol.46 , Issue.6 , pp. 999-1004
    • Braun, J.1    McHugh, N.2    Singh, A.3    Wajdula, J.S.4    Sato, R.5
  • 26
    • 14944366460 scopus 로고    scopus 로고
    • Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    • DOI 10.1093/rheumatology/keh475
    • BRANDT J,LISTING J,HAlBEL H et al:. Longterm efficacy and safety of etanercept after readministration in patients with ankylosing spondylitis. Rheumatology (Oxford) 2005; 44: 342-8. (Pubitemid 40361291)
    • (2005) Rheumatology , vol.44 , Issue.3 , pp. 342-348
    • Brandt, J.1    Listing, J.2    Haibel, H.3    Sorensen, H.4    Schwebig, A.5    Rudwaleit, M.6    Sieper, J.7    Braun, J.8
  • 27
    • 79952109388 scopus 로고    scopus 로고
    • Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: A retrospective analysis
    • LEE J, NOH JW, HWANG JW et al:. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010; 29: 1149-54.
    • (2010) Clin Rheumatol , vol.29 , pp. 1149-1154
    • Lee, J.1    Noh, J.W.2    Hwang, J.W.3
  • 28
    • 83455250623 scopus 로고    scopus 로고
    • Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis
    • CUI Y, XIAO Z, SHUXIA W et al:. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis. Scand J Rheumatol 2009; 27: 958-63.
    • (2009) Scand J Rheumatol , vol.27 , pp. 958-963
    • Cui, Y.1    Xiao, Z.2    Shuxia, W.3
  • 29
    • 17244374728 scopus 로고    scopus 로고
    • Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
    • DOI 10.1002/art.20977
    • BARALIAKOS X, DAVIS J, TSUJI W, BRAUN J: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216-23. (Pubitemid 40530129)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.4 , pp. 1216-1223
    • Baraliakos, X.1    Davis, J.2    Tsuji, W.3    Braun, J.4
  • 30
    • 23944517016 scopus 로고    scopus 로고
    • Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
    • DOI 10.1136/ard.2004.032441
    • RUDWALEIT M, BARALIAKOS X, LISTING J, BRANDT J, SIEPER J, BRAUN J: Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005; 64: 1305-10. (Pubitemid 41206247)
    • (2005) Annals of the Rheumatic Diseases , vol.64 , Issue.9 , pp. 1305-1310
    • Rudwaleit, M.1    Baraliakos, X.2    Listing, J.3    Brandt, J.4    Sieper, J.5    Braun, J.6
  • 32
    • 24644446382 scopus 로고    scopus 로고
    • Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy
    • DOI 10.1002/art.21330
    • DAVIS JC, VAN DER HEIJDE D, DOUGADOS M, WOOLLEY JM: Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494-501. (Pubitemid 41278913)
    • (2005) Arthritis Care and Research , vol.53 , Issue.4 , pp. 494-501
    • Davis, J.C.1    Van Der Heijde, D.2    Dougados, M.3    Woolley, J.M.4
  • 33
    • 41849104176 scopus 로고    scopus 로고
    • Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept
    • BOONEN A, PATEL V, TRAINA S, CHIOU CF, MAETZEL A, TSUJI W: Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008; 35: 662-7.
    • (2008) J Rheumatol , vol.35 , pp. 662-627
    • Boonen, A.1    Patel, V.2    Traina, S.3    Chiou, C.F.4    Maetzel, A.5    Tsuji, W.6
  • 34
    • 78149489356 scopus 로고    scopus 로고
    • Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis
    • BARKHAM N, COATES LC, KEEN H et al:. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1926-8
    • (2010) Ann Rheum Dis , vol.69 , pp. 1926-1928
    • Barkham, N.1    Coates, L.C.2    Keen, H.3
  • 35
    • 0034729950 scopus 로고    scopus 로고
    • Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
    • MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis; a randomised trial. Lancet 2000; 356: 385-90. (Pubitemid 30487495)
    • (2000) Lancet , vol.356 , Issue.9227 , pp. 385-390
    • Mease, P.J.1    Goffe, B.S.2    Metz, J.3    Vanderstoep, A.4    Finck, B.5    Burge, D.J.6
  • 37
    • 33644861049 scopus 로고    scopus 로고
    • Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: A 26-week observational study
    • DOI 10.1093/rheumatology/kei153
    • DE VLAM K, LORIES RJU: Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 2006;46:321-4. (Pubitemid 43372848)
    • (2006) Rheumatology , vol.45 , Issue.3 , pp. 321-324
    • De Vlam, K.1    Lories, R.J.U.2
  • 38
    • 33645804643 scopus 로고    scopus 로고
    • Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
    • MEASE PJ, KIVITZ AJ, BURCH FX et al:. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33: 712-21.
    • (2006) J Rheumatol , vol.33 , pp. 712-721
    • Mease, P.J.1    Kivitz, A.J.2    Burch, F.X.3
  • 39
    • 34147219117 scopus 로고    scopus 로고
    • Survival on TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
    • On BEHALF OF THE BIOBADASER GROUP
    • CARMONA L, REINO-GOMEZ JJ ON BEHALF OF THE BIOBADASER GROUP: Survival on TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72.
    • (2006) Arthritis Res Ther , vol.8
    • Carmona, L.1    Reino-Gomez, J.J.2
  • 41
    • 54349107274 scopus 로고    scopus 로고
    • Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis
    • SPADARO A, CECCARELLI F, SCRIVO R, VALESINIG G: Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008; 67: 1650-1.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1650-1651
    • Spadaro, A.1    Ceccarelli, F.2    Scrivo, R.3    Valesinig, G.4
  • 42
    • 65449189497 scopus 로고    scopus 로고
    • Persistence with anti-tumour necrosis factortherapies in patients with psoriatic arthritis: Observational study from the British Society of rheumatology biologies register
    • SAAD AA, ASHCROFT DM, WATSON KD, HYRICH KL, NOYCE PR, SYMMONS DPM: Persistence with anti-tumour necrosis factortherapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologies Register. Arthritis Res Ther 2009,11:R52
    • (2009) Arthritis Res Ther , vol.11
    • Saad, A.A.1    Ashcroft, D.M.2    Watson, K.D.3    Hyrich, K.L.4    Noyce, P.R.5    Symmons, D.P.M.6
  • 43
    • 83455176384 scopus 로고    scopus 로고
    • Etanercept benefits skin, joints, and entheseal symptoms in patients with psoriasis and psoriatic arthritis, the PRESTA trial
    • KIRKHAM BW, STERRY W, ORMEROD A et al:. Etanercept benefits skin, joints, and entheseal symptoms in patients with psoriasis and psoriatic arthritis, the PRESTA trial. Arthritis Rheum 2009; 60 (Suppl. 10): S194
    • (2009) Arthritis Rheum , vol.60 , Issue.SUPPL. 10
    • Kirkham, B.W.1    Sterry, W.2    Ormerod, A.3
  • 44
    • 72449210551 scopus 로고    scopus 로고
    • Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
    • MAZZOTTA A, ESPOSITO M, SCHIPANI C, CHIMENTI S: Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. J Dermatolog Treat 2009; 20: 354-8.
    • (2009) J Dermatolog Treat , vol.20 , pp. 354-358
    • Mazzotta, A.1    Esposito, M.2    Schipani, C.3    Chimenti, S.4
  • 45
    • 77953181751 scopus 로고    scopus 로고
    • Patients reported outcomes in a randomized trial of etanercept in psoriatic arthritis
    • MEASE PJ, WOOLEY JM, SINGH A, TSUJI W, DUNN M, CHOIU CF: Patients reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010; 37: 1221-7.
    • (2010) J Rheumatol , vol.37 , pp. 1221-1227
    • Mease, P.J.1    Wooley, J.M.2    Singh, A.3    Tsuji, W.4    Dunn, M.5    Choiu, C.F.6
  • 46
    • 79955669942 scopus 로고    scopus 로고
    • The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept
    • LUBRANO E, SPADARO A, MARCHESONI A et al:. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011; 29: 80-4.
    • (2011) Clin Exp Rheumatol , vol.29 , pp. 80-84
    • Lubrano, E.1    Spadaro, A.2    Marchesoni, A.3
  • 48
    • 0035459313 scopus 로고    scopus 로고
    • Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy: A Clinical and Magnetic Resonance Imaging Study
    • DOI 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H
    • MARZO-ORTEGA H, MCGONAGLE D, OXONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112-7. (Pubitemid 33644055)
    • (2001) Arthritis and Rheumatism , vol.44 , Issue.9 , pp. 2112-2117
    • Marzo-Ortega, H.1    McGonagle, D.2    O'Connor, P.3    Emery, P.4
  • 49
    • 1542515178 scopus 로고    scopus 로고
    • Successful Short Term Treatment of Patients with Severe Undifferentiated Spondyloarthritis with the Anti-Tumor Necrosis Factor-alpha Fusion Receptor Protein Etanercept
    • BRANDT J,KHARIOUZOV A,LISTING J et al.: Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31: 531-8. (Pubitemid 38337615)
    • (2004) Journal of Rheumatology , vol.31 , Issue.3 , pp. 531-538
    • Brandt, J.1    Khariouzov, A.2    Listing, J.3    Haibel, H.4    Sorensen, H.5    Rudwaleit, M.6    Sieper, J.7    Braun, J.8
  • 50
    • 24644509214 scopus 로고    scopus 로고
    • Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: An open-label trial
    • DOI 10.1002/art.21323
    • FLAGG SD, MEADOR R, HSIA E, KITUMNUAYPONG T, SCHUMACHER HR JR.: Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005; 53: 613-7. (Pubitemid 41278928)
    • (2005) Arthritis Care and Research , vol.53 , Issue.4 , pp. 613-617
    • Flagg, S.D.1    Meador, R.2    Hsia, E.3    Kitumnuaypong, T.4    Schumacher Jr., H.R.5
  • 51
    • 37349120419 scopus 로고    scopus 로고
    • Switching tumor necrosis factor a inhibitors in HLA-B27-associated severe heel enthesitis
    • DOI 10.1002/art.23096
    • OLIVIERI I, SCARANO E, PADULA A, D'ANGELO S, CANTINI F: Switching tumor necrosis factor a inhibithors in HLA-B27-associated severe heel enthesitis. Arthritis Rheum 2007; 57: 1572-4. (Pubitemid 350308861)
    • (2007) Arthritis Care and Research , vol.57 , Issue.8 , pp. 1572-1574
    • Olivieri, I.1    Scarano, E.2    Padula, A.3    D'Angelo, S.4    Cantini, F.5
  • 52
    • 77955445434 scopus 로고    scopus 로고
    • A randomised, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloathritis: The HEEL trial
    • DOUGADOS M, COMBE B. BRAUN J et al:. A randomised, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloathritis: the HEEL trial. Ann Rheum Dis 2010; 69: 1430-5.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1430-1435
    • Dougados, M.1    Combe, B.2    Braun, J.3
  • 53
    • 0030738875 scopus 로고    scopus 로고
    • The outcome of ankylosing spondylitis: A study of 100 patients
    • GRAN JT, SKOMSVOLL JF: The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 766-71.
    • (1997) Br J Rheumatol , vol.36 , pp. 766-771
    • Gran, J.T.1    Skomsvoll, J.F.2
  • 54
    • 46849108338 scopus 로고    scopus 로고
    • Prevalence and characteristics of uveitis in the spondyloarthropathies: A systematic literature review
    • ZEBOULON N, DOUGADOS M, GOSSEC L: Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008; 67: 955-9.
    • (2008) Ann Rheum Dis , vol.67 , pp. 955-359
    • Zeboulon, N.1    Dougados, M.2    Gossec, L.3
  • 55
    • 0029097323 scopus 로고
    • HLA-B27 and spondyloarthropathy: Value for early diagnosis?
    • GRAN JT, HUSBY G: HLA-B27 and spondyloarthropathy: value for early diagnosis? J Med Genet 1995; 32: 497-501.
    • (1995) J Med Genet , vol.32 , pp. 497-501
    • Gran, J.T.1    Husby, G.2
  • 56
    • 8444244864 scopus 로고    scopus 로고
    • Effect of etanercept on iritis in patients with ankylosing spondylitis [5]
    • DOI 10.1002/art.20754
    • ROSENBAUM JT: Effect of etanercept on iritis in patients with ankylosing spondylitis [letter]. Arthritis Rheum 2004; 50: 3736-7. (Pubitemid 39488709)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.11 , pp. 3736-3737
    • Rosenbaum, J.T.1
  • 57
    • 0034980872 scopus 로고    scopus 로고
    • Methotrexate therapy for chronic noninfectious uveitis: Analysis of a case series of 160 patients
    • DOI 10.1016/S0161-6420(01)00576-0, PII S0161642001005760
    • SAMSON CM, WAHEED N, BALTATZIS S, FOSTER CS: Methotrexate therapy for chronic noninfectious uveitis: an analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-9. (Pubitemid 32500033)
    • (2001) Ophthalmology , vol.108 , Issue.6 , pp. 1134-1139
    • Samson C.Michael1    Waheed, N.2    Baltatzis, S.3    Foster C.Stephen4
  • 58
    • 23644452510 scopus 로고    scopus 로고
    • Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept
    • DOI 10.1002/art.21197
    • BRAUN J.BARALIAKOS X,LISTING J.SIEPER J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.8 , pp. 2447-2451
    • Braun, J.1    Baraliakos, X.2    Listing, J.3    Sieper, J.4
  • 59
    • 73449114984 scopus 로고    scopus 로고
    • Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials
    • SIEPER J, KOENIG AS, BAUMGARTNER S et al:. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010; 69: 226-9.
    • (2010) Ann Rheum Dis , vol.69 , pp. 226-229
    • Sieper, J.1    Koenig, A.S.2    Baumgartner, S.3
  • 61
    • 35348914933 scopus 로고    scopus 로고
    • Do tumor necrosis factor inhibitors cause uveitis? A registry-based study
    • DOI 10.1002/art.22918
    • LIM LL, FRAUNFELDER FW, ROSENBAUM JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56: 3248-52. (Pubitemid 47585419)
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.10 , pp. 3248-3252
    • Lim, L.L.1    Fraunfelder, F.W.2    Rosenbaum, J.T.3
  • 62
    • 43949120761 scopus 로고    scopus 로고
    • Uveitis following the use of tumor necrosis factor α inhibitors: Comment on the article by Lim et al
    • DOI 10.1002/art.23440
    • SCRIVO R, SPADARO A, SPINELLI FR, VALESINI G: Uveitis following the use of tumor necrosis factor α inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008; 58: 1555-6. (Pubitemid 351705951)
    • (2008) Arthritis and Rheumatism , vol.58 , Issue.5 , pp. 1555-1556
    • Scrivo, R.1    Spadaro, A.2    Spinelli, F.R.3    Valesini, G.4
  • 64
    • 67650088393 scopus 로고    scopus 로고
    • Paradoxical adverse events of antitumour necrosis factor therapy for spondyloarthropaties: A retrospective study
    • FOUACHE D, GOEB V, MASSY-GUILLEMANT N et al:. Paradoxical adverse events of antitumour necrosis factor therapy for spondyloarthropaties: a retrospective study. Rheumatology (Oxford) 2009; 48: 761-4.
    • (2009) Rheumatology (Oxford) , vol.48 , pp. 761-764
    • Fouache, D.1    Goeb, V.2    Massy-Guillemant, N.3
  • 65
    • 37549003226 scopus 로고    scopus 로고
    • Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis
    • LANGE U, STAPFER G, DITTING T et al:. Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis. Eur J Med Res 2007; 14: 573-81.
    • (2007) Eur J Med Res , vol.14 , pp. 573-581
    • Lange, U.1    Stapfer, G.2    Ditting, T.3
  • 68
    • 0031675375 scopus 로고    scopus 로고
    • Renal diseases in ankylosing spondylitis: Review of the literature illustrated by case reports
    • STROBEL ES, FRITSCHKA E: Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 1998; 17: 524-30. (Pubitemid 28566334)
    • (1998) Clinical Rheumatology , vol.17 , Issue.6 , pp. 524-530
    • Strobel, E.-S.1    Fritschka, E.2
  • 69
    • 36248992938 scopus 로고    scopus 로고
    • Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: A report of three patients
    • DOI 10.1007/s10067-007-0679-x
    • KOBAK S, OKSEL F, KABASAKAL Y, DOGANAVSARGIL E: Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 2007; 26: 2191-4. (Pubitemid 350120369)
    • (2007) Clinical Rheumatology , vol.26 , Issue.12 , pp. 2191-2194
    • Kobak, S.1    Oksel, F.2    Kabasakal, Y.3    Doganavsargil, E.4
  • 70
    • 39549103518 scopus 로고    scopus 로고
    • Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis
    • BELLISS1MO S, FERRUCCI MG, GALLO A, STISI S: Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis. Reumatismo 2007; 59: 240-3.
    • (2007) Reumatismo , vol.59 , pp. 240-243
    • Bellisslmo, S.1    Ferrucci, M.G.2    Gallo, A.3    Stisi, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.